PYCARD, PYD and CARD domain containing, 29108

N. diseases: 294; N. variants: 2
Disease: Hormone refractory prostate cancer ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1328504
Disease: Hormone refractory prostate cancer
Hormone refractory prostate cancer 		0.050 Biomarker disease BEFREE Together, these results suggest that a combined therapy of docetaxel and ASC-J9® is a novel therapy to better suppress CRPC in patients that already developed docetaxel resistance. 30248372 2019
CUI: C1328504
Disease: Hormone refractory prostate cancer
Hormone refractory prostate cancer 		0.050 Biomarker disease BEFREE Together, results from preclinical studies suggest a potential new therapy with AR-degradation enhancer ASC-J9<sup>®</sup> may potentially be ready to be used in human clinical trials in order to better suppress PCa at later castration resistant stages. 29203251 2018
CUI: C1328504
Disease: Hormone refractory prostate cancer
Hormone refractory prostate cancer 		0.050 Biomarker disease BEFREE Thus, developing ASC-J9(®) as a new therapeutic approach may represent a novel therapy to better suppress CRPC that has already developed Enz resistance. 27233475 2016
CUI: C1328504
Disease: Hormone refractory prostate cancer
Hormone refractory prostate cancer 		0.050 Biomarker disease BEFREE New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. 23219429 2013
CUI: C1328504
Disease: Hormone refractory prostate cancer
Hormone refractory prostate cancer 		0.050 Biomarker disease BEFREE ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. 22355276 2012